

## Bios Massimo Dominici



He was born in Lodi in 1972. In 1996 he graduated cum laude in Medicine and Surgery in Pavia. After training at the Hematology Institute of the University of Vienna (Austria) and at the University of Ferrara, he obtained the specialization in Hematology cum Laude. From 2000 to 2003 he was a post-doctoral Fellow the St. Jude Children's Research Hospital in Memphis (USA). In 2003 he arrived in Modena as a hospital contractor of the Policlinico Hospital, from 2005 he became assistant Professor in Medical Oncology and head of the Cellular Therapies Laboratory. Since 2005 he has also been a medical doctor in the Oncology Division of the University / General Hospital of Modena. Since 2007 he has been Tutor / Lecturer at the PhD School of Molecular and Regenerative Medicine, UNIMORE and has been tutor of 22 PhD students. Since November 2015 he was Associate Professor in Medical Oncology at UNIMORE with courses in Medicine and Surgery, Medical Biotechnology, Physiotherapy, Radiology and Radiotherapy Technicians and in various Masters at the University of Modena and Reggio Emilia, Parma and Urbino. Overall, he has been supervisor of over 60 degree theses in Medicine and Surgery, Biotechnology and Biology. Director of the School of Specialization in Medical Oncology since November 2016. Since June 2020 he is Full Professor and Director of the Division of Oncology. Founder and scientific director of the biocompatibility laboratory at the Mirandola Science and Technology Park.

He publishes 291 manuscripts in international journals, books (3) and book chapters (5) with over 49,100/33,700 citations and an H-index of 65/53 (G. Scholar / Scopus). He also has 4 papers published in interview format in Science (3) and Nature (1). More than 240 invited seminars in national and international congresses. Thirty research projects funded as principal investigator and as co-investigator at national and international level (PRIN, AIRC, Finalized Research Ministry of Health, POR-FESR, FP7, H2020, HORIZON EU, IMI-2, Departments of Excellence MIUR 2017 and 2022, 2 PNRR) with 15 grants from biotech/pharma industries for third party contracts for a total of over 24 million euros in funding since 2004. It has 12 registered patents. Founder in 2009 of the university start-up Rigenerand srl which was acquired in July 2022 by EVOTEC SE (NASDAQ listed). Member of numerous national and international scientific societies as well as being founder and vice-president of the scientific society Forum of Italian Researchers on Stromal and Stem cells (FIRST). Since 2001, member of the International Society for Cell and Gene Therapy (ISCT). After various management positions, he was elected the first non-American president of the ISCT (2014-16), now a member of the Company's Strategic Advisory Council. Editor and reviewer of numerous international journals and for public and private research funding bodies.

He has received awards such as 1st place in the "Modena Intraprendere 2009" competition as founder of the academic spin-off Rigenerand srl (2009). In 2012 Guido Berlucci Foundation Prize on Cancer Research. In 2017 Fanfullino D'Oro Della Riconoscenza Award (City of Lodi), Citizenship Award - Secugnago (Lodi) and always in 2017 Pico Della Mirandola International Award - Mirandola (Modena) and International Award Mashhad University 2017. From 2011 to 2012 Member of the Interested Parties at the EMA in the Committee of Advanced Therapy in London and, from 2012 to 2014, Member of the Board of Directors of the Joint Accreditation Committee-ISCT & EBMT (JAICE), in September 2012 member of the National commission for the use of stem cells at the Ministry of Health. From 2014 to 2018 Member of the board of the Worldwide Network for Blood and Marrow Transplantation (WBMT). From 2015 to 2019 member of the Scientific Technical Committee of the Berlucci Foundation for Cancer Research and from 2015 of the Support Association for Pediatric Oncology and Hematology (ASEOP). From 2016 to 2018 member of the Scientific Technical Committee of the Italian Association of Osteogenesis Imperfecta, of the Scientific Council of the French Scientific Foundation « Fondation des maladies chroniques et du vieillissement actif - Languedoc-Roussillon » and of the International Medical Advisory Board of the Canadian Stem Cell Network, Canada. Since 10/2020 appointed expert for the World Health Organization in the group "International Nonproprietary Names (INN) for pharmaceutical substances" on cell and gene therapies. Modena (Italy), 01/10/2024

*Massimo Dominici*